Revelation Biosciences Outlines Plans Human Trial For Lead Fibrosis Candidate

Revelation Biosciences Inc REVB announced that a recently completed exploratory biomarker analysis confirmed clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) and acute kidney injury (AKI).
The new biomarker data is in addition to the previously-announced significant reduction in new collagen deposition (57%) observed in a preclinical fibrosis model and provides the potential for new intellectual property.
Reduction in new collagen deposition (fibrosis) helps maintain kidney function.
Fibrosis or scarring results in loss of normal kidney function.
During 1H of 2023, Revelation plans to initiate a Phase 1a study comprising five cohorts of single ascending doses and the 6th cohort of multiple doses of REVTx-300 to investigate the safety and drug activity.
Revelation plans to initiate a Phase 1b clinical study in patients undergoing elective cardiac surgery in 2H of 2023.
In October, Revelation announced results from the preclinical model of acute kidney injury and chronic kidney disease.
Price Action: REVB shares are up 5.38% at $0.2350 on the last check Friday.